Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is well positioned fundamentally because VYJUVEK continues to scale with Q3 worldwide revenue of $127 million, net profit of $63 million, and a 94% gross margin, while over 760 U.S. reimbursement approvals and 80+ new prescribers support continued commercial penetration. The company’s growth runway also looks extended by international expansion, with 20+ centers in Germany treating patients, final pricing secured in Germany and Italy, and Japan’s prescribing restriction expected to ease soon, which should lift revenue beyond the $1.2 billion cash balance and strong financial flexibility. Beyond the core franchise, reduced FY26 non-GAAP OpEx guidance to $155–165 million and a $400 million buyback reinforce capital efficiency, while the pipeline offers multiple shots on goal in NK, HHD, CF, AATD, and oncology.

Krystal Biotech is facing a weaker fundamental outlook as delayed approval timelines for Ph3 '801 in NK, Ph3 '803 in ocDEB, and Ph1/2 '407 in CF reduce confidence in its pipeline contribution, even after partial offset from adding Ph1/2 '111 for HHD. Near-term commercial execution also looks less attractive because VYJUVEK’s ex-US rollout is being slowed by France’s hospital administration requirements and Japan’s twice-monthly in-office represcribing, while EMERALD-1 enrollment is lagging due to narrow eligibility, site activation delays, and patient hesitancy. With topline data now guided to 2027, the company faces elevated clinical, regulatory, and commercial risk, and any trial setback or stronger competitor data could prevent it from meeting financial projections.